GeneMedi’s AAV8 variant (Y733F, Y447F, Y275) Rep-Cap plasmid (retina-validated serotype AAV-RC plasmid), also named AAV8 variant (Y733F, Y447F, Y275)-RC plasmid, is part of AAV8 variant (Y733F, Y447F, Y275) packaging system. AAV8 variant (Y733F, Y447F, Y275) Rep-Cap plamid supplies the AAV8 Rep(replication) proteins and the AAV8 variant (Y733F, Y447F, Y275) capsid protein.
You can produce AAV8 variant (Y733F, Y447F, Y275) paticle in 293T cell line in high titer using GeneMedi’s AAV8 variant (Y733F, Y447F, Y275) Rep-Cap plasmid with GeneMedi’s AAV expression vector (overexpression or shRNA) and AAV helper plasmid.
The tissue tropism of AAV8-3m vector has been validated in in Pancreas, Pancreatic Tumors and retina,with potential applications in tissue-specific gene therapy and cancer therapy.
AAV8 capsid variant (Y733F, Y447F, Y275F) tissue tropism and gene transduction
(serotype-specific AAV infection)
The tissue tropism of AAV8 variant (Y733F, Y447F, Y275F) vector has been validated in in Pancreas, Pancreatic Tumors and retina,with potential applications in tissue-specific gene therapy and cancer therapy.
Virus and titer: AAV1/AAV6/AAV8/AAV-Rh10/AAV-DJ/AAV9-GFP, 1×1012 vg/ml
Cells: HEK-293T
MOI: MOI=1×104
Determine assay: 36 hours post infection, immunofluorescence microscopy